Welcome to our dedicated page for Prestige Consumer Healthcare SEC filings (Ticker: PBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prestige Consumer Healthcare's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prestige Consumer Healthcare's regulatory disclosures and financial reporting.
PBH submitted a Rule 144 notice reporting the proposed sale of 346 shares of Common Stock tied to restricted stock vesting. The filing lists a dollar value of $19,140.72 and references trading on the NYSE. It also discloses a prior sale of 1,000 shares on 02/11/2026 with a reported amount of $65,930.00.
Prestige Consumer Healthcare Inc: Vanguard Capital Management reports beneficial ownership of 2,454,974 shares of common stock, representing 5.18% of the class as of 03/31/2026. The filing shows sole voting power over 361,981 shares and sole dispositive power over 2,454,974 shares. The disclosure states these holdings include securities held for Vanguard funds and managed accounts. The report was signed on 04/30/2026.
Prestige Consumer Healthcare Inc Schedule 13G shows Vanguard Portfolio Management reported beneficial ownership of 2,826,536 shares of Common Stock, representing 5.97% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 2,826,536 shares and sole voting power over 22,708 shares. The form was signed on 04/29/2026.
The Vanguard Group filed Amendment No. 17 to its Schedule 13G/A regarding Prestige Consumer Healthcare Inc. The amendment reports amount beneficially owned: 0 shares representing 0% of Common Stock. It explains an internal realignment effective January 12, 2026 that caused disaggregated reporting by Vanguard subsidiaries. The form is signed by Ashley Grim on 03/27/2026.
Prestige Consumer Healthcare Inc. announced a definitive agreement for its subsidiary Prestige Brands, Inc. to acquire the Breathe Right nasal strip brand and certain other over-the-counter consumer health brands from Foundation Consumer Healthcare for $1.045 billion in cash, or approximately $900 million net of anticipated $150 million tax benefits. The assets include Breathe Right, the leading nasal strip brand in the United States with international sales, and brands such as Dimetapp children’s cough and cold relief. The deal is expected to close in the first half of fiscal 2027, subject to customary closing conditions and antitrust clearance, and will be financed with cash on hand and a new Term Loan facility. Management describes the acquisition as margin-accretive and expects it to increase free cash flow and support faster balance-sheet deleveraging.
Prestige Consumer Healthcare Inc. Senior VP of Operations Jeffrey Zerillo reported an open-market sale of common stock. On February 11, 2026, he sold 1,000 shares of Prestige Consumer common stock at $65.93 per share. After this transaction, he directly owned 41,048 shares of the company’s common stock.
Ariel Investments, LLC has reported beneficial ownership of 4,102,497 shares of Prestige Consumer Healthcare Inc common stock, representing 8.5% of the outstanding class as of December 31, 2025. Ariel has sole voting power over 3,672,254 shares and sole dispositive power over all 4,102,497 shares.
The filing explains that these securities are held for Ariel’s adviser clients, who are entitled to dividends and sale proceeds, and that no individual client has an economic interest in more than 5% of the shares. Ariel certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Prestige Consumer Healthcare.
A person associated with PBH has filed a notice of intent to sell 1,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 65,930.00. The filing shows 47,318,730 shares of this class outstanding. The shares to be sold were acquired through restricted stock vesting on May 2, 2024, May 5, 2025, and May 7, 2025, in amounts of 116, 533, and 351 shares respectively, all as compensation. Over the past three months, the filer previously sold 719 shares on November 28, 2025 for gross proceeds of 43,140.00 and 281 shares on December 1, 2025 for gross proceeds of 16,860.00.
Prestige Consumer Healthcare Inc. reported softer results for the quarter ended December 31, 2025. Total revenues slipped 2.4% to $283.4 million, with declines in both North American and International OTC segments, mainly from weaker Eye & Ear Care sales. Quarterly net income fell to $46.7 million, or $0.97 per diluted share, down from $61.0 million and $1.22 a year earlier, reflecting lower sales, higher general and administrative costs and a $10.3 million supplier loan write-off.
For the first nine months of fiscal 2026, revenues declined 4.1% to $807.1 million and net income decreased to $136.4 million from $164.5 million, while gross margin ticked higher on favorable mix. The company completed two acquisitions, including Pillar5 Pharma for a preliminary $111.9 million, added goodwill and intangibles, generated strong operating cash flow of $214.8 million, and used $155.6 million to repurchase shares, ending with $62.4 million in cash and $1.04 billion of long-term debt.
Prestige Consumer Healthcare Inc. filed a current report to share that it has announced financial results for the fiscal quarter and nine months ended December 31, 2025. The detailed numbers are provided in a separate earnings press release attached as Exhibit 99.1.
The company is also using an investor presentation, attached as Exhibit 99.2, to discuss these results with investors, analysts and others during the fiscal year ending March 31, 2026. Both the press release and presentation are being treated as “furnished,” meaning they are provided for information and are not classified as formally filed financial statements under securities laws.